-
With its bid for Illumina, Roche is betting its IVD framework and hospital customer base will give it a leg up in accessing the biggest potential growth area in MDx: whole genome sequencing.
Published on 1/30/2012
-
Roche re-sequences Roche-Illumina portfolio The acquisition of Illumina Inc. (NASDAQ:ILMN) would broaden and complement Roche's menu of genomics technologies for research and diagnostics customers. While Roche (SIX:…
Published on 1/30/2012
-
Epigenetics land grab Epigenetics landscape Large companies have been stepping up deal activity in the epigenetics space over the last three years. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has disclosed the most …
Published on 1/23/2012
-
Genentech has joined the race into epigenetics, concluding that Constellation is best positioned to both validate the ever-increasing number of epigenetic targets and to identify small molecules to modulate them.
Published on 1/23/2012
-
As Teva's new CEO, Jeremy Levin's job will be to restore investor confidence in management. But he also will be aiming to dispel notions that the company's growth story will be all about branded drugs.
Published on 1/16/2012
-
Rebooting confidence Confidence wanes Shlomo Yanai, outgoing CEO of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), led the company through a period of rapid growth in sales and profitability as measured by EPS …
Published on 1/16/2012
-
Rebooting confidence Teva diversifies Since Shlomo Yanai became president and CEO in March 2007, Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) has been reconfigured from a company in which generics and the U.S. …
Published on 1/16/2012
-
In a guest Commentary, three industry veterans argue it is in big biopharma's interest to create funds to invest in IPOs of young science-driven biotechs capable of turning novel biology into compelling business …
Published on 1/9/2012
-
Over the 20 years since BioCentury's first Buyside View survey of biotech investor sentiment, the explosion of scientific knowledge, more sophisticated investors and the disappearance of low-hanging fruit have made it …
Published on 1/9/2012
-
Buysiders aren't excited by the many PDUFA dates in 2012, and instead are looking for more clinical action in the already hot HCV space, autoimmune disease and cancer.
Published on 1/9/2012
-
PDUFAs produce yawns 20-year timeline As BioCentury begins its 20th year of publishing, we reflect on the dramatic changes that have occurred in the biopharmaceutical industry since January 1993. As the timeline …
Published on 1/9/2012
-
PDUFAs produce yawns 2012 milestones Selected products with Phase III or regulatory milestones expected in 2012. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone Abbott …
Published on 1/9/2012
-
PDUFAs produce yawns Approval watch Selected products up for approval in 2012. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone Access Pharmaceuticals Inc. (OTCBB:ACCP)/ …
Published on 1/9/2012
-
PDUFAs produce yawns New products to watch Selected drugs that received regulatory approval in 2011. Source: BCIQ: BioCentury Online Intelligence Company Product Indication 2011 approval Amgen Inc. (NASDAQ:AMGN…
Published on 1/9/2012
-
PDUFAs produce yawns Post-launch report While Provenge sipuleucel-T from Dendreon Corp. (NASDAQ:DNDN) disappointed investors in 2011, two new drugs - Prolia/Xgeva denosumab and Incivek telaprevir - are likely to …
Published on 1/9/2012
-
PDUFAs produce yawns Top biotech products At least 34 drugs developed and marketed by biotech companies are anticipated to have more than $500 million in sales in 2011. Of those, 20 are expected to bring in more …
Published on 1/9/2012
-
Although public biotechs raised more money than ever in 2011, development stage biotechs are getting a shrinking share of the expanding pie. To hang on in 2012, creative financing strategies and dilution will be the …
Published on 1/2/2012
-
Living creatively Debt dominance The amount of debt raised by public biotechs has been rising. Last year, debt accounted for $35.3 billion (82%) of the $43 billion total raised in the public markets. Seven public …
Published on 1/2/2012
-
Living creatively Fear factor The Chicago Board Options Exchange Market Volatility Index (VIX) is a measure of the expected volatility in the S&P 500 over the next 30 days. It fell below the 30 mark at the end of …
Published on 1/2/2012
-
Living creatively Funding by stage While public biotechs raised a record-breaking $43 billion in 2011, more than 75% of the money went to 71 companies with marketed drugs. Debt deals by five companies with marketed …
Published on 1/2/2012
-
Living creatively Healthcare/biotech fund flows About $231 million exited healthcare/biotech funds in 2011. In August, $2.4 billion flowed out of these funds as the U.S. debt debate along with negative news on sales…
Published on 1/2/2012
-
Living creatively M&A activity The total value of completed M&A transactions in 2011 reached a record $79 billion, largely driven by the takeouts of Genzyme Corp. and Nycomed. The 91 total deals, including private …
Published on 1/2/2012
-
Living creatively The 1% effect Nine public biotechs valued above $5 billion - representing less than 2% of the more than 570 companies tracked by BioCentury - pulled in more than two-thirds ($29.1 billion) of the …
Published on 1/2/2012
-
Living creatively Follow-on performance Follow-on deals slowed in the second half of 2011, with only 25 deals completed for $1.2 billion vs. 54 deals for $3 billion in 1H11. For the year, follow-ons raised a total …
Published on 1/2/2012
-
Living creatively IPO performance Nineteen biotechs raised $972.7 million via IPOs in 2011, including five companies last quarter. This compares to 31 IPOs that raised $1.6 billion in 2010. The 2011 class traded …
Published on 1/2/2012